Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure

Journal of Cardiology

Volumn 56, Issue 3, 2010, Pages 291-299

  Tanaka, Keiji ^a   Kato, Kazuzo ^b,h   Takano, Teruo ^a,i   Katagiri, Takashi ^c,j   Asanoi, Hidetsugu ^d,k   Nejima, Jun ^a,l   Nakashima, Mitsuyoshi ^e   Kamijo, Takeshi ^f   Sakanashi, Matao ^g,m  

^a NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^b THE CARDIOVASCULAR INSTITUTE   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^g UNIVERSITY OF THE RYUKYUS SCHOOL OF MEDICINE   (Japan)

^h Keiwa Clinic   (Japan)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

^j SHOWA UNIVERSITY   (Japan)

^k Imizu City Hospital   (Japan)

^l TSURUMI UNIVERSITY   (Japan)

^m UNIVERSITY OF THE RYUKYUS   (Japan)

more..

Author keywords

Acute decompensated heart failure; Heart failure; KATP channel opener; Nicorandil; Treatment; Vasodilator agents

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CATECHOLAMINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; NICORANDIL; NITRATE; VASODILATOR AGENT;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART FAILURE; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; FEMALE; HEART FAILURE; HEMODYNAMICS; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NICORANDIL; PULMONARY WEDGE PRESSURE; VASODILATOR AGENTS;

EID: 78049436897     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.06.009     Document Type: Article

References (23)

1. Guidelines for treatment of acute heart failure (JCS) 2006, http://www.j-circ.or.jp/guideline/pdf/JCS2006_maruyama_h.pdf.
2. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
3. Jessup M., Abraham W.T., Casey D.E., Feldman A.M., Francis G.S., Ganiats T.G., Konstam M.A., Mancini D.M., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
4. Mebazaa A., Gheorghiade M., Piña I.L., Harjola V.P., Hollenberg S.M., Follath F., Rhodes A., Plaisance P., Roland E., Nieminen M., Komajda M., Parkhomenko A., Masip J., Zannad F., Filippatos G. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008, 36(1 (Suppl.)):S129-S139.
5. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989, 63:18J-24J.
6. Sakai K., Shiraki Y., Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl) nicotinamide nitrate (SG-75): comparison with nitroglycerin and diltiazem. J Cardiovasc Pharmacol 1981, 3:139-150.
7. Nakae I., Matsumoto T., Horie H., Yokohama H., Omura T., Minai K., Matsui T., Nozawa M., Takahashi M., Sugimoto Y., Ito M., Izumi M., Nakamura Y., Mitsunami K., Kinoshita M. Effects of intravenous nicorandil on coronary circulation in humans: plasma concentration and action mechanism. J Cardiovasc Pharmacol 2000, 35:919-925.
8. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Shimizu M., Nishii T., Taniyama Y., Asai T., Takiuchi S., Moriguchi K., Ohkuro M., Komai N., Yamada K., Inamoto N., Otsuka A., et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol 2001, 37:719-725.
9. Ito H., Taniyama Y., Iwakura K., Nishikawa N., Masuyama T., Kuzuya T., Hori M., Higashino Y., Fujii K., Minamino T. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999, 33:654-660.
10. Ishii H., Ichimiya S., Kanashiro M., Amano T., Imai K., Murohara T., Matsubara T. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005, 112:1284-1288.
11. Iwakura K., Ito H., Okamura A., Koyama Y., Date M., Higuchi Y., Inoue K., Kimura R., Nagai H., Imai M., Toyoshima Y., Ozawa M., Ito N., Okazaki Y., Shibuya M., et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009, 73:925-931.
12. Solal A.C., Jaeger P., Bouthier J., Juliard J.M., Dahan M., Gourgon R. Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 1989, 63:44J-48J.
13. Tice F.D., Binkley P.F., Cody R.J., Moeschberger M.L., Mohrland J.S., Wolf D.L., Leier C.V. Hemodynamic effects of oral nicorandil in congestive heart failure. Am J Cardiol 1990, 65:1361-1367.
14. Giles T.D., Pina I.L., Quiroz A.C., Roffidal L., Zaleski R., Porter R.S., Karalis D.G., Mohrland J.S., Wolf D.L., Hearron A.E., Sander G.E. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. J Cardiovasc Pharmacol 1992, 20:572-578.
15. Tsutamoto T., Kinoshita M., Nakae I., Maeda Y., Wada A., Yabe T., Horie H. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994, 127:866-873.
16. Larsen A.I., Goransson L., Aarsland T., Tamby J.F., Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 1997, 134:435-441.
17. Metra M., Teerlink J.R., Voors A.A., Felker G.M., Milo-Cotter O., Weatherley B., Dittrich H., Cotter G. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009, 14:299-307.
18. Kamijo T., Tomaru T., Miwa A.Y., Nakamura F., Kido H., Uchida Y. Hemodynamic effects of nicorandil on acute congestive heart failure in dogs. Asia Pacific J Pharmacol 1996, 11:141-148.
19. Kamijo T., Kamei K., Sugo I., Kamiyama T., Sudo H., Ohba Y. Hemodynamic and hormonal responses to nicorandil in a canine model of acute ischemic heart failure: a comparison with cromakalim and nitroglycerin. J Cardiovasc Pharmacol 1999, 33:93-101.
20. Gotanda K., Yokoyama H., Satoh K., Taira N. Cardiohemodynamic effects of cromakalim and pinacidil, potassium-channel openers, in the dog, special reference to venous return. Cardiovasc Drugs Ther 1989, 3:507-515.
21. Yanagisawa T., Hashimoto H., Taira N. Interaction of potassium channel openers and blockers in canine atrial muscle. Br J Pharmacol 1989, 97:753-762.
22. Minami Y., Nagashima M., Kajimoto K., Shiga T., Hagiwara N. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol 2009, 54:335-340.
23. Miura T., Kawamura S., Tatsuno H., Ikeda Y., Mikami S., Iwamoto H., Okamura T., Iwatate M., Kimura M., Dairaku Y., Maekawa T., Matsuzaki M. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001, 104:1053-1058.